Hozawa Soichiro, Ono Keita, Makita Naoyuki, Uchimura Hitomi, Arita Yoshifumi, Hirai Takehiro, Tashiro Naoki
Hiroshima Allergy and Respiratory Clinic, Hiroshima, Japan.
AstraZeneca K.K., Tokyo, Japan.
J Asthma Allergy. 2024 Jan 18;17:9-19. doi: 10.2147/JAA.S437944. eCollection 2024.
Japanese guidelines recommend that patients with uncontrolled asthma be referred by non-specialists to specialists (allergists and/or pulmonologists). This study investigated the reality of clinical practice in asthma patients referred to specialists in Japan.
This was a retrospective, observational cohort study of asthma patients in a health insurance claim database (Cross Fact) referred from facilities with non-specialists to those with specialists from January 2016 to December 2018. The referred asthma patients were defined as patients with ≥4 inhaled corticosteroid (ICS)-containing prescriptions during a 1-year baseline period, with an asthma diagnosis, and who had visited a facility with specialists. Asthma exacerbation, maintenance treatment, laboratory tests, and medical procedures before and after referral were analyzed.
Data for 2135 patients were extracted, of which 420 with referral codes were analyzed. The proportion of patients with asthma exacerbations was 50.2% (95% confidence interval [CI]: 45.4-55.1%) before referral and 37.4% (95% CI: 32.7-42.2%) after, a significant decrease (P<0.001; McNemar test). The proportions of patients prescribed ICS alone, long-acting beta-agonists (LABA), and ICS/LABA were lower after referral than before, but the proportions of patients prescribed long-acting muscarinic antagonists (LAMA), ICS/LABA/LAMA, and biologics increased after referral. More asthma-related laboratory tests were performed after referral, and spirometry incidence increased from 16.4% before referral to 51.4% after referral.
This study shows a decrease in asthma exacerbations, change in asthma treatments, and increase in laboratory tests after referral to a specialist, suggesting that referrals to specialists lead to better management of asthma.
日本指南建议,哮喘控制不佳的患者应由非专科医生转诊至专科医生(过敏症专科医生和/或肺病专科医生)处。本研究调查了日本转诊至专科医生处的哮喘患者的临床实际情况。
这是一项回顾性观察队列研究,研究对象为2016年1月至2018年12月期间在医疗保险理赔数据库(Cross Fact)中从非专科医疗机构转诊至专科医疗机构的哮喘患者。被转诊的哮喘患者定义为在1年基线期内有≥4份含吸入性糖皮质激素(ICS)处方、被诊断为哮喘且曾就诊于专科医疗机构的患者。分析了转诊前后的哮喘急性加重情况、维持治疗、实验室检查及医疗程序。
提取了2135例患者的数据,其中420例有转诊编码的患者被纳入分析。转诊前哮喘急性加重患者的比例为50.2%(95%置信区间[CI]:45.4 - 55.1%),转诊后为37.4%(95%CI:32.7 - 42.2%),显著下降(P<0.001;McNemar检验)。转诊后单独使用ICS、长效β受体激动剂(LABA)和ICS/LABA的患者比例低于转诊前,但使用长效毒蕈碱拮抗剂(LAMA)、ICS/LABA/LAMA和生物制剂的患者比例在转诊后有所增加。转诊后进行了更多与哮喘相关的实验室检查,肺功能测定的发生率从转诊前的16.4%增至转诊后的51.4%。
本研究表明,转诊至专科医生后哮喘急性加重情况减少、哮喘治疗发生变化且实验室检查增多,提示转诊至专科医生有助于更好地管理哮喘。